TLR7 and neoplasm: Wang et al. reported that DOX coupled with imidazoquinolines, a TLR7/8 agonist, effectively activated DC and CD8+ T cells and improved the therapeutic efficacy in B16-OVA and CT26 tumor-bearing mice models [29].